196 related articles for article (PubMed ID: 36653090)
1. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.
Navarese EP; Podhajski P; Gurbel PA; Grzelakowska K; Ruscio E; Tantry U; Magielski P; Kubica A; Niezgoda P; Adamski P; Junik R; Przybylski G; Pilaczyńska-Cemel M; Rupji M; Specchia G; Pinkas J; Gajda R; Gorog DA; Andreotti F; Kubica J
J Am Coll Cardiol; 2023 Jan; 81(3):224-234. PubMed ID: 36653090
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
[TBL] [Abstract][Full Text] [Related]
6. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Fitzgerald K; Frank-Kamenetsky M; Shulga-Morskaya S; Liebow A; Bettencourt BR; Sutherland JE; Hutabarat RM; Clausen VA; Karsten V; Cehelsky J; Nochur SV; Kotelianski V; Horton J; Mant T; Chiesa J; Ritter J; Munisamy M; Vaishnaw AK; Gollob JA; Simon A
Lancet; 2014 Jan; 383(9911):60-68. PubMed ID: 24094767
[TBL] [Abstract][Full Text] [Related]
7. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
[TBL] [Abstract][Full Text] [Related]
8. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
9. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
[TBL] [Abstract][Full Text] [Related]
12. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
13. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
[TBL] [Abstract][Full Text] [Related]
14. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
16. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
17. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
19. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
20. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
